Contact
searchSearch
HMP Global
Login

Advertisement

Advertisement

Advertisement

Advertisement

ADVERTISEMENT

Expert Insights

Shernan Holtan, MD
Videos
Frontline Treatment Options for Acute Graft-Versus-Host Disease
11/13/2023

Featuring Shernan Holtan, MD

Featuring Shernan Holtan, MD
Shernan Holtan, MD, explores advances and unmet needs in the frontline treatment of patients with acute graft-versus-host-disease.
Shernan Holtan, MD, explores advances and unmet needs in the frontline treatment of patients with acute graft-versus-host-disease.
Shernan Holtan, MD, explores...
11/13/2023
Oncology
KOL Roundtable
Videos
New Possibilities and Advances in Mantle Cell Lymphoma Treatment: Part 5
11/13/2023

Featuring Kami Maddocks, MD, Jia Ruan, MD, PhD, and Krish Patel, MD

Featuring Kami Maddocks, MD, Jia Ruan...
Kami Maddocks, MD, reviews new possibilities and the latest advances in the treatment of patients with mantle cell lymphoma with Jia Ruan, MD, PhD, and Krish Patel, MD.
Kami Maddocks, MD, reviews new possibilities and the latest advances in the treatment of patients with mantle cell lymphoma with Jia Ruan, MD, PhD, and Krish Patel, MD.
Kami Maddocks, MD, reviews new...
11/13/2023
Oncology
KOL Roundtable
Videos
Role of Non-Covalent BTK Inhibitors in Mantle Cell Lymphoma Treatment: Part 4
11/13/2023

Featuring Kami Maddocks, MD, Jia Ruan, MD, PhD, and Krish Patel, MD

Featuring Kami Maddocks, MD, Jia Ruan...
Kami Maddocks, MD, discusses the role of non-covalent BTK inhibitors in the treatment of patients with mantle cell lymphoma with Jia Ruan, MD, PhD, and Krish Patel, MD.
Kami Maddocks, MD, discusses the role of non-covalent BTK inhibitors in the treatment of patients with mantle cell lymphoma with Jia Ruan, MD, PhD, and Krish Patel, MD.
Kami Maddocks, MD, discusses the...
11/13/2023
Oncology
KOL Roundtab
Videos
Treating Patients With Relapsed/Refractory Mantle Cell Lymphoma: Part 3
11/13/2023

Featuring Kami Maddocks, MD, Jia Ruan, MD, PhD, and Krish Patel, MD

Featuring Kami Maddocks, MD, Jia Ruan...
In this expert roundtable series, Kami Maddocks, MD, leads a discussion with Jia Ruan, MD, PhD, and Krish Patel, MD on the best options for treating patients with relapsed/refractory mantle cell lymphoma.
In this expert roundtable series, Kami Maddocks, MD, leads a discussion with Jia Ruan, MD, PhD, and Krish Patel, MD on the best options for treating patients with relapsed/refractory mantle cell lymphoma.
In this expert roundtable...
11/13/2023
Oncology
Oleg Gluz, MD
Conference Coverage
Static and Dynamic Biomarkers to Optimize Adjuvant Therapy in Luminal Early Breast Cancer
11/10/2023

Featuring Oleg Gluz, MD

Featuring Oleg Gluz, MD
Oleg Gluz, MD, Evangelical Bethesda Hospital, Breast Center Niederrhein, Mönchengladbach, Germany, discusses results from the prospective WSG-ADAPT HR+/HER- trial.
Oleg Gluz, MD, Evangelical Bethesda Hospital, Breast Center Niederrhein, Mönchengladbach, Germany, discusses results from the prospective WSG-ADAPT HR+/HER- trial.
Oleg Gluz, MD, Evangelical...
11/10/2023
Oncology
DSI Breast Roundtable Video 3
SPONSORED VIDEO
HER2-Low Breast Cancer Roundtable: Deep Dive Into HER2 Testing in Metastatic Breast Cancer Treatment
11/10/2023
This roundtable discussion is sponsored by Daiichi Sankyo. Dr Adam Brufsky: So now let's turn really to HER2 low. We're all very familiar with DESTINY-Breast04, and the publication came out in the New England Journal. I think some of us...
This roundtable discussion is sponsored by Daiichi Sankyo. Dr Adam Brufsky: So now let's turn really to HER2 low. We're all very familiar with DESTINY-Breast04, and the publication came out in the New England Journal. I think some of us...
This roundtable discussion is...
11/10/2023
Oncology
DSI Breast Roundtable Video 2
SPONSORED VIDEO
HER2-Low Breast Cancer Roundtable: Navigating Latest Guidelines & HER2-Targeted Treatments in Metastatic Breast Cancer
11/10/2023
This roundtable discussion is sponsored by Daiichi Sankyo. Dr Adam Brufsky: So now let's turn really to HER2 low. We're all very familiar with DESTINY-Breast04, and the publication came out in the New England Journal. I think some of us...
This roundtable discussion is sponsored by Daiichi Sankyo. Dr Adam Brufsky: So now let's turn really to HER2 low. We're all very familiar with DESTINY-Breast04, and the publication came out in the New England Journal. I think some of us...
This roundtable discussion is...
11/10/2023
Oncology
DSI Breast Roundtable Video 1
SPONSORED VIDEO
HER2-Low Breast Cancer Roundtable: Decoding HER2-Low Expression in Metastatic Breast Cancer
11/10/2023
This roundtable discussion is sponsored by Daiichi Sankyo. Dr Adam Brufsky: So, hello, my name is Dr Adam Brufsky. I'm a professor of medicine at the University of Pittsburgh, and welcome today to our Oncology Learning Network Roundtable...
This roundtable discussion is sponsored by Daiichi Sankyo. Dr Adam Brufsky: So, hello, my name is Dr Adam Brufsky. I'm a professor of medicine at the University of Pittsburgh, and welcome today to our Oncology Learning Network Roundtable...
This roundtable discussion is...
11/10/2023
Oncology
Philip Kuo, MD, PhD, University of Arizona Cancer Center
Videos
Association Between Baseline PSMA Expression and Response to 177Lu-PSMA-617 Among Patients with Metastatic Castration-Resistant Prostate Cancer
11/10/2023

Featuring Philip Kuo, MD, PhD

Featuring Philip Kuo, MD, PhD
Philip Kuo, MD, PhD, shares results from a sub-study of the phase 3 VISION trial, investigating the association between baseline PSMA expression and response to 177Lu-PSMA-617 therapy among patients with metastatic castration-resistant...
Philip Kuo, MD, PhD, shares results from a sub-study of the phase 3 VISION trial, investigating the association between baseline PSMA expression and response to 177Lu-PSMA-617 therapy among patients with metastatic castration-resistant...
Philip Kuo, MD, PhD, shares...
11/10/2023
Oncology
KOL Roundtable
Videos
Approaches to Frontline Therapy for Patients With Mantle Cell Lymphoma: Part 2
11/09/2023

Featuring Kami Maddocks, MD, Jia Ruan, MD, PhD, and Krish Patel, MD

Featuring Kami Maddocks, MD, Jia Ruan...
In the second part of an expert roundtable series, Kami Maddocks, MD, leads a discussion with Jia Ruan, MD, PhD, and Krish Patel, MD on goals and choice of frontline therapy for patients with mantle cell lymphoma.
In the second part of an expert roundtable series, Kami Maddocks, MD, leads a discussion with Jia Ruan, MD, PhD, and Krish Patel, MD on goals and choice of frontline therapy for patients with mantle cell lymphoma.
In the second part of an expert...
11/09/2023
Oncology

Advertisement

Advertisement

Advertisement

Advertisement

Recent News

News
Osimertinib Lacks Activity in Neoadjuvant Setting for Early-Stage Non-Small Cell Lung Cancer With EGFR Mutation
08/08/2024
Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.
Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.
Results from a phase 2 study...
08/08/2024
Oncology
FDA Approval
FDA Approves Denileukin Diftitox for Patients With R/R Cutaneous T-Cell Lymphoma
08/08/2024
The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.
The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.
The US Food and Drug...
08/08/2024
Oncology
News
Tailored Dose-Dense Chemotherapy Improved Survival Outcomes Among Patients With High-Risk Early Breast Cancer
08/07/2024
According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.
According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.
According to results from the...
08/07/2024
Oncology
News
Frontline Treatment Management for Patients With FL Reduces Risk of High-Grade Transformation to DLBCL
08/07/2024
A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.
A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.
A recent study demonstrated that...
08/07/2024
Oncology
News
Optimal Sotorasib Dose for Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer
08/07/2024
Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.
Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.
Results from a phase 2 study...
08/07/2024
Oncology
FDA Approval
FDA Approves Vorasidenib for Patients With IDH1/IDH2-Mutated Grade 2 Astrocytoma or Oligodendroglioma
08/06/2024
Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.
Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.
Based on results from the INDIGO...
08/06/2024
Oncology
FDA Approval
FDA Approves Afamitresgene Autoleucel for Certain Unresectable or Metastatic Synovial Sarcoma
08/02/2024
On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...
On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...
On August 2, 2024, the US Food...
08/02/2024
Oncology
FDA Approval
FDA Approves Dostarlimab Plus Chemotherapy for Patients With Primary Advanced or Recurrent Endometrial Cancer
08/01/2024
The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.
The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.
The FDA approved dostarlimab...
08/01/2024
Oncology
News
Iadademstat and Azacitidine Combination Therapy Demonstrates Manageable Safety, Promising Efficacy for Patients With Newly Diagnosed AML
08/01/2024
The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.
The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.
The first-line combination of...
08/01/2024
Oncology
News
Effect of Food on Selumetinib Dosing for Adolescent Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas
08/01/2024
In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...
In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...
In the phase 1 trial, the...
08/01/2024
Oncology

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use

Advertisement

Advertisement